Intech Biopharm Ltd

Intech Biopharm Ltd

TTPEX:6461
27.25
TWD
+2.45
(+9.88%)
-4.79EPS
1.67BMarket Cap
Intech Biopharm Ltd
TPEX:6461
(Taipei Exchange)

Recent

price

27.25

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
- -
0.54
0.23
0.27
0.27
0.36
0.34
0.31
0.32
0.59
0.32
0.34
0.46
1.15
0.55
Revenue per Share
- -
-1.32
-2.15
-2.79
-2.91
-5.19
-4.4
-5.88
-3.85
-4.6
-4.49
-4.46
-4.26
-4.15
-4.79
Basic EPS, GAAP
- -
-19.69
-29.89
-9.67
-11.18
-8.85
-8.67
-4.54
-3.31
-3.38
-2.76
-3.09
-3.62
-4.53
-3.61
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2.06
22.48
36.06
32.97
34.47
29.38
28.23
24.04
20.32
17.82
13.67
13.51
9.39
9.98
11.1
Book Value per Share
2.06
22.48
36.04
32.96
34.47
29.28
28.13
23.97
20.24
17.76
13.6
13.46
9.34
9.93
10.95
Tangible Book Value per Share
37
13
37
36
43
46
50
53
65
66
73
76
86
94
99
Basic Weighted Avg Shares
- -
7
9
10
12
17
17
17
21
39
24
26
40
108
54
Sales/Revenue/Turnover
- -
-438.32
-1,124.61
-1,078.89
-1,133.72
-1,485.72
-1,340.1
-1,796.37
-1,139.78
-755.76
-1,345.12
-1,239.87
-895.26
-338.99
-838.6
Operating Margin (%)
- -
1
5
9
12
17
24
74
85
85
85
85
87
91
93
Depreciation Expense
- -
-17
-79
-101
-125
-239
-222
-311
-250
-302
-328
-338
-368
-389
-475
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-243.68
-918.63
-1,036.94
-1,076.63
-1,440.96
-1,288.59
-1,866.6
-1,186.25
-775.74
-1,386.55
-1,307.64
-925.63
-361.8
-873.26
Profit Margin (%)
79
625
115
13
240
-15
-21
153
255
133
105
126
24
160
239
Working Capital
- -
- -
- -
250
468
709
773
830
1,138
941
1,143
970
1,188
995
1,377
LT Debt
79
863
1,384
1,265
1,590
1,355
1,488
1,569
1,329
1,338
1,032
1,168
814
1,101
758
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-3.65
-7
-7.65
-8.79
-16.25
-15.62
-20.37
-17.28
-22.63
-27.68
-30.73
-37.15
-40.62
-54.37
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
355
174
222
LT Borrowings
913
1,154
1,376
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
110
110
68
Market Capitalization
3,178
2,696
1,669

Working Capital

TWD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
396
371
519
Cash, Cash Equivalents & STI
193
145
314
Accounts Receivable, Net
12
8
9
Inventories
104
137
115
Total Current Liabilities
411
229
280
Payables & Accruals
- -
- -
- -
ST Debt
355
174
222
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.68%
-0.81%
35.21%
Free Cash Flow
5.36%
15.89%
35.9%
Net Income, GAAP
17.49%
9.37%
5.66%
Sales/Revenue/Turnover
36.75%
55.72%
170.31%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
15
5
9
11
40
2025
8
88
7
5
108
2026
18
19
13
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.87
-1.1
-1.13
-1.21
-4.26
2025
-1.03
-0.33
-1.43
-1.12
-4.15
2026
-1.02
-0.95
-2
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Intech Biopharm Corporation (6461.TWO), founded in 2010 and headquartered in Taipei, Taiwan, develops and manufactures generic and novel drugs focused on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), with operations in Taiwan and international markets. The company offers core products including metered-dose inhalers via its patented iLEF (inhaled low ethanol formulation) platform, which precisely controls drug particle size for targeted lung delivery; dry powder inhalers (DPI) utilizing blister and capsule filling technologies paired with the patented Pandahaler device; and branded offerings such as SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011. Intech Biopharm, a spin-off from parent company Synmosa Biopharma Corp, employs approximately 90 staff and maintains R&D and production facilities compliant with EMA and US FDA standards, targeting high-barrier generics, new combinations, and formulations for obstructive airway diseases. Recent developments include ongoing expansion into global markets leveraging its unique MDI and DPI platforms, alongside pursuits in anti-cancer drug R&D, though no major acquisitions, partnerships, or funding rounds have been publicly reported in 2024 or 2025.